S&P 500   4,446.41 (-0.20%)
DOW   34,957.85 (+0.46%)
QQQ   369.18 (-1.11%)
AAPL   144.69 (-1.52%)
MSFT   293.57 (-1.93%)
FB   351.09 (-0.53%)
GOOGL   2,820.76 (-0.83%)
TSLA   791.76 (+2.24%)
AMZN   3,375.00 (-1.47%)
NVDA   215.07 (-2.60%)
BABA   148.49 (+2.35%)
NIO   36.18 (+2.26%)
CGC   14.74 (+5.97%)
GE   106.01 (+2.13%)
MU   74.80 (+1.01%)
AMD   106.78 (+0.93%)
T   27.59 (+1.70%)
F   14.20 (+3.05%)
ACB   6.39 (+7.39%)
DIS   178.67 (+1.52%)
PFE   43.81 (-0.30%)
BA   226.58 (+2.34%)
BAC   43.25 (+2.63%)
S&P 500   4,446.41 (-0.20%)
DOW   34,957.85 (+0.46%)
QQQ   369.18 (-1.11%)
AAPL   144.69 (-1.52%)
MSFT   293.57 (-1.93%)
FB   351.09 (-0.53%)
GOOGL   2,820.76 (-0.83%)
TSLA   791.76 (+2.24%)
AMZN   3,375.00 (-1.47%)
NVDA   215.07 (-2.60%)
BABA   148.49 (+2.35%)
NIO   36.18 (+2.26%)
CGC   14.74 (+5.97%)
GE   106.01 (+2.13%)
MU   74.80 (+1.01%)
AMD   106.78 (+0.93%)
T   27.59 (+1.70%)
F   14.20 (+3.05%)
ACB   6.39 (+7.39%)
DIS   178.67 (+1.52%)
PFE   43.81 (-0.30%)
BA   226.58 (+2.34%)
BAC   43.25 (+2.63%)
S&P 500   4,446.41 (-0.20%)
DOW   34,957.85 (+0.46%)
QQQ   369.18 (-1.11%)
AAPL   144.69 (-1.52%)
MSFT   293.57 (-1.93%)
FB   351.09 (-0.53%)
GOOGL   2,820.76 (-0.83%)
TSLA   791.76 (+2.24%)
AMZN   3,375.00 (-1.47%)
NVDA   215.07 (-2.60%)
BABA   148.49 (+2.35%)
NIO   36.18 (+2.26%)
CGC   14.74 (+5.97%)
GE   106.01 (+2.13%)
MU   74.80 (+1.01%)
AMD   106.78 (+0.93%)
T   27.59 (+1.70%)
F   14.20 (+3.05%)
ACB   6.39 (+7.39%)
DIS   178.67 (+1.52%)
PFE   43.81 (-0.30%)
BA   226.58 (+2.34%)
BAC   43.25 (+2.63%)
S&P 500   4,446.41 (-0.20%)
DOW   34,957.85 (+0.46%)
QQQ   369.18 (-1.11%)
AAPL   144.69 (-1.52%)
MSFT   293.57 (-1.93%)
FB   351.09 (-0.53%)
GOOGL   2,820.76 (-0.83%)
TSLA   791.76 (+2.24%)
AMZN   3,375.00 (-1.47%)
NVDA   215.07 (-2.60%)
BABA   148.49 (+2.35%)
NIO   36.18 (+2.26%)
CGC   14.74 (+5.97%)
GE   106.01 (+2.13%)
MU   74.80 (+1.01%)
AMD   106.78 (+0.93%)
T   27.59 (+1.70%)
F   14.20 (+3.05%)
ACB   6.39 (+7.39%)
DIS   178.67 (+1.52%)
PFE   43.81 (-0.30%)
BA   226.58 (+2.34%)
BAC   43.25 (+2.63%)
NASDAQ:BOLD

Audentes Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$59.97
0.00 (0.00 %)
(As of 01/15/2020)
Add
Compare
Today's Range
$59.97
$59.97
50-Day Range
$59.97
$59.97
52-Week Range
$22.00
$60.00
VolumeN/A
Average Volume1.50 million shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.18

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Audentes Therapeutics logo

About Audentes Therapeutics

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.27 out of 5 stars

Medical Sector

1134th out of 1,352 stocks

Biological Products, Except Diagnostic Industry

169th out of 195 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

What stocks does MarketBeat like better than Audentes Therapeutics?

Wall Street analysts have given Audentes Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Audentes Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.07. During the same period in the previous year, the business posted ($0.97) earnings per share.
View Audentes Therapeutics' earnings history
.

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the following people:
  • Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)
  • Ms. Natalie C. Holles, Pres & COO (Age 46)
  • Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)
  • Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)
  • Mr. Andrew H. Chang, Director of Investor Relations

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV), bluebird bio (BLUE), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN).

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $59.97.

How much money does Audentes Therapeutics make?

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis.

How many employees does Audentes Therapeutics have?

Audentes Therapeutics employs 207 workers across the globe.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is www.audentestx.com.

Where are Audentes Therapeutics' headquarters?

Audentes Therapeutics is headquartered at 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.